UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
March
6, 2015
Commission
File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrant’s
principle executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⃞ Form 40-F ⊠
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ⃞ No ⊠
If "Yes" is
marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): Not applicable
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: |
March 6, 2015 |
|||
Aurinia Pharmaceuticals Inc. |
||||
|
||||
|
|
By: |
/s/ Michael R. Martin |
|
Name: |
Michael R. Martin |
|||
|
|
Title: |
Chief Operating Officer |
EXHIBIT INDEX
Exhibit |
Description of Exhibit |
|
99.1 |
News Release – Aurinia announces change to its Board of Directors |
3
Exhibit 99.1
Aurinia Announces Change to Its Board of Directors
VICTORIA, British Columbia--(BUSINESS WIRE)--March 6, 2015--Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ:AUPH / TSX:AUP) today announced that Mr. Kurt von Emster has tendered his resignation as a member of the Aurinia Board of Directors, effective March 6th, 2015. This decision is driven by Mr. von Emster’s departure from the employment of venBio LLC (“venBio”), and the retained right of venBio to put forward a nominee of their choice for election onto the Aurinia Board of Directors.
“The Company very much wants to thank Kurt for his contributions and thoughtful input over the course of his tenure. We are very appreciative of everything that Kurt has brought to us,” said Dr. Richard Glickman, Chairman of Aurinia’s Board of Directors.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best in class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,600 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.
Aurinia also has development and commercialization partners in Canada, Israel, South Africa and Greater China. Visit www.auriniapharma.com, www.sedar.com and www.sec.gov for more information.
CONTACT:
Aurinia Pharmaceuticals Inc.
Stephen Zaruby, 250-708-4293
President
& Chief Executive Officer
szaruby@auriniapharma.com
Investor
& Media Contact:
Michael R. Martin, 250-708-4272
Chief
Operating Officer
mmartin@auriniapharma.com